

2025 MIPS Seminar Program

 08 July 2025

 9:00 to 10:00 am

 Zoom

REIMAGINING DRUGGABILITY USING CHEMOPROTEOMIC PLATFORMS

Professor Daniel K. Nomura



Professor Dan Nomura is a leading expert in chemical biology and molecular therapeutics at UC Berkeley, where he holds joint appointments in Chemistry and Molecular and Cell Biology. He directs the Novartis-Berkeley Translational Chemical Biology Institute and co-directs the Molecular Therapeutics Initiative, focusing on chemoproteomics to address the challenge of the "undruggable" proteome. As an entrepreneur and advisor, he has co-founded companies such as Frontier Medicines and Zenith Therapeutics and serves on numerous scientific and investment advisory boards. In 2025, he became the Editor-in-Chief of Molecular Cancer Therapeutics.

The Nomura Research Group pioneers chemoproteomic platforms to unlock therapeutic opportunities for proteins previously considered undruggable—those lacking conventional binding pockets for small-molecule drugs. Their innovative approaches enable discovery of new ligandable hotspots and the development of covalent ligands that can precisely target these proteins. This work has significant implications for expanding the range and precision of potential therapies for complex diseases.

Their current efforts span three key areas: covalent ligand discovery to rapidly generate small-molecule leads, advancing targeted protein degradation using chemoproteomic insights, and developing proximity-based therapeutic modalities. Together, these strategies aim to redefine druggability and create transformative new treatments through cutting-edge chemical biology.

Webinar Link: <https://monash.zoom.us/j/86554464560?pwd=7QH1Clrd3MaJli86mtH1DAe6xZJg5p.1>

Webinar ID: 865 5446 4560

Passcode: 142958